Congenital Adrenal Hyperplasia Clinical Trials

A listing of Congenital Adrenal Hyperplasia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 26 clinical trials
Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia (CAHtalyst)

This is a Phase 3 study to evaluate the efficacy, safety, and tolerability of crinecerfont versus placebo administered for 24 weeks in approximately 165 adult subjects with classic CAH due to 21-hydroxylase deficiency. The study consists of a 6 month randomized, double blind, placebo-controlled period, followed by 1 year of …

21-ohd
deficiency
  • 123 views
  • 27 Apr, 2022
  • 56 locations
Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Patients With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)

adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The study consists of a 28-week double blind, placebo-controlled period, followed by 24 weeks of treatment with crinecerfont. Duration of

21-ohd
classic congenital adrenal hyperplasia
deficiency
  • 0 views
  • 11 Jul, 2022
  • 35 locations
A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH

An investigation of the efficacy and safety of up to 70 weeks of treatment with Tildacerfont in subjects with classic CAH who have elevated biomarkers at baseline on their current GC regimen. Optional open label treatment extension period up to 240 weeks with 200mg tildacerfont QD.

17-hydroxyprogesterone
deficiency
21-ohd
prednisolone
prednisone
  • 28 views
  • 28 Jul, 2022
  • 55 locations
A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH

An investigation of the ability of Tildacerfont to reduce supraphysiologic glucocorticoid dosing in classic CAH subjects up to 76 weeks of treatment. Optional open label extension up to 240 weeks.

21-ohd
prednisolone
prednisone
deficiency
  • 10 views
  • 25 Jul, 2022
  • 53 locations
Congenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment (CareOnTIME)

, metabolic syndrome, hormonal profile, bone status, quality of life, reproductive, sexual and psychological functions and treatment compliance in patients affected by congenital adrenal hyperplasia due to 21

21-ohd
prednisolone
metabolic syndrome
glucocorticoids
adrenal insufficiency
  • 56 views
  • 14 Apr, 2022
  • 1 location
A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH)

This study is designed to evaluate the safety, tolerability, and efficacy of AAV5 based BBP-631 in adult participants diagnosed with classic congenital adrenal hyperplasia.

21-ohd
classic congenital adrenal hyperplasia
oral hydrocortisone
  • 6 views
  • 27 May, 2022
  • 1 location
Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia (CONnECT)

over with Congenital Adrenal Hyperplasia.

prednisolone
replacement therapy
glucocorticoids
fludrocortisone
glucocorticoid therapy
  • 0 views
  • 27 Jul, 2022
  • 6 locations
A Phase 2 Study to Evaluate the Safety, PK, and Exploratory PD of Tildacerfont in Children With CAH

An investigation of the safety of Tildacerfont in pediatric subjects with CAH.

21-ohd
  • 0 views
  • 22 Jul, 2022
  • 4 locations
Effects of Adrenal Artery Ablation and Spironolactone in Patients With Primary Aldosteronism

and aldosterone receptor inhibitors are the only treatment for primary aldosteronism. However, only about 35% of aldosterone tumors and a small number of unilateral adrenal hyperplasia can be treated

hyperaldosteronism
computed tomography of adrenals
spironolactone
hypertension
heart failure
  • 0 views
  • 24 Jan, 2021
  • 1 location
Application of 68Ga-Pentixafor PET/CT in Primary Aldosteronism and Pre-postoperative of SAAE

Primary aldosteronism is the most common cause of secondary hypertension. The two main types of primary aldosteronism are aldosteronoma(30%) and adrenal hyperplasia(60%). The gold standard that

  • 0 views
  • 11 Aug, 2022
  • 1 location